Monitor for completion of the ibogaine development program and any subsequent clinical supply agreements or regulatory milestones. The regulatory tailwind from the U.S. Executive Order and Texas funding is a positive narrative catalyst, but the stock remains highly speculative with no near-term revenue visibility.
Price Chart
Executive Summary
Optimi Health Corp. announced it has secured naturally derived ibogaine from two sources and will commence finished drug product development at its GMP facility in British Columbia. The press release highlights a U.S. Executive Order from April 18, 2026, prioritizing ibogaine for accelerated FDA review, and a $50 million Texas state program for ibogaine clinical trials. This is a forward-looking operational update with no current revenue or financial data.
Key Facts
- Optimi has secured naturally derived ibogaine in HCl and freebase form from two sources.
- Development work on finished drug product (50mg and 100mg capsules) is anticipated to commence this summer at its GMP facility in British Columbia.
- A U.S. Executive Order on April 18, 2026, named ibogaine among psychedelic therapies prioritized for accelerated FDA review and expanded patient access.
- The state of Texas awarded $50 million to lead ibogaine clinical trials.
- Ibogaine remains a Schedule I substance in the U.S. but is not a controlled substance in Canada, positioning Canada as a manufacturing base.
- No financial figures (revenue, EPS, margins, deal values) were provided in the filing.
Financial Impact
No financial impact quantified; operational update with no revenue or cost data.
Risk Factors
- Ibogaine remains a Schedule I substance in the U.S., creating regulatory and legal barriers for commercial distribution.
- Development timeline is uncertain; the company has not provided a completion date or cost estimate.
- No current revenue from ibogaine; the company is pre-revenue on this product line.
- Forward-looking statements are subject to risks described in the company's F-1 registration statement and other SEC filings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-260708 |
| Document: d160428d6k.htm | 0001193125-26-260708 |
| Document: 0001193125-26-260708-index-headers.html | 0001193125-26-260708 |
| Document: 0001193125-26-260708-index.html | 0001193125-26-260708 |
| Document: 0001193125-26-260708.txt | 0001193125-26-260708 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $3.36 | awaiting T+5 | — | $3.26 (−2.84%) |
Oct 20, 2026 6d ago | 6-K | $3.36 | awaiting T+5 | — | $3.26 (−2.84%) |
Oct 7, 2026 19d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.26 (−19.19%) |
Oct 5, 2026 20d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.26 (−20.95%) |
Sep 29, 2026 27d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.26 (−31.70%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.26 (−34.18%) |
Sep 22, 2026 4w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.26 (−34.18%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.26 (−33.38%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.26 (−27.45%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.26 (+33.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers